Redeye provides its initial take on Moberg Pharma's Q3 report, with sales and profitability well ahead of our expectations. Sales grew 44% YoY and Terclara®'s market shares in Sweden and Norway rose further from Q2. Israel was launched in September as guided, and first deliveries to Karo Healthcare remain on track for around year-end. We expect positive estimate revisions, driven mainly by the sales beat.
LÄS MER
